For the quarter ending 2026-03-31, ALEC had $11,160K increase in cash & cash equivalents over the period. -$49,931K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -22,930 | -37,267 | -34,667 | -70,995 |
| Depreciation and amortization | 1,081 | 1,168 | 1,237 | 3,313 |
| Stock-based compensation | 2,908 | 4,843 | 6,402 | 15,413 |
| Amortization of premiums and accretion of discounts on marketable securities | 667 | 1,246 | 1,548 | 3,785 |
| Amortization of right-of-use assets | 1,003 | 1,091 | 1,095 | 1,757 |
| Amortization of debt discount and debt issuance costs | 78 | 78 | 75 | 140 |
| Impairment loss of right-of-use assets and leasehold improvements | - | 1,771 | 0 | 1,151 |
| Prepaid expenses and other current assets | -1,859 | 1,151 | -2,621 | 478 |
| Other assets | -17 | -4,085 | -23 | -50 |
| Accounts payable | -268 | -3,066 | 2,540 | 2 |
| Accrued liabilities and accrued clinical supply costs | -11,023 | 1,089 | 2,514 | -16,507 |
| Payable to collaboration partner | -7,060 | 6,501 | 4,181 | 693 |
| Deferred revenue | -1,046 | -6,237 | -3,260 | -11,548 |
| Refund liability to collaboration partner | 12,035 | 11,923 | 12,041 | 26,063 |
| Lease liabilities | -1,763 | -1,720 | -1,683 | -3,182 |
| Other long-term liabilities | 33 | 293 | 0 | 210 |
| Net cash used in operating activities | -49,813 | -41,691 | -32,511 | -109,829 |
| Purchase of property and equipment | 118 | 0 | 11 | 30 |
| Sale of marketable securities | - | 0 | 0 | 2,981 |
| Purchase of marketable securities | 51,805 | 81,048 | 58,952 | 131,879 |
| Maturities of marketable securities | 112,871 | 106,646 | 108,505 | 250,385 |
| Net cash provided by investing activities | 60,948 | 25,598 | 49,542 | 121,457 |
| Proceeds from the exercise of options to purchase common stock | 25 | 15 | - | - |
| Proceeds from issuance of stock from employee stock purchase plan | - | 95 | 0 | 122 |
| Proceeds from issuance of common stock, net of issuance costs | - | 5,282 | 14,701 | - |
| Proceeds from issuance of common stock upon public offering, net of issuance costs | - | - | - | 0 |
| Proceeds from debt financing, net of discount and issuance costs | - | 0 | - | - |
| Net cash provided by financing activities | 25 | 5,392 | 14,701 | 122 |
| Net increase in cash, cash equivalents, and restricted cash | 11,160 | -10,701 | 31,732 | 11,750 |
| Cash, cash equivalents, and restricted cash at beginning of period | 67,648 | 78,349 | 34,867 | - |
| Cash, cash equivalents, and restricted cash at end of period | 78,808 | 67,648 | 78,349 | - |
Alector, Inc. (ALEC)
Alector, Inc. (ALEC)